Peptide Therapy Programs

How candidacy for Peptide Therapy is evaluated

• Health history, current medications, and labs are reviewed at consultation.
• Peptide selection and dosing are physician-guided and individualized.
• Pregnancy, breastfeeding, and certain conditions may exclude or modify protocols.
• Informed consent is required before any prescription or protocol is started.
• Results vary; we do not make disease-treatment claims.

Screening, history, and provider guidance determine whether any protocol is appropriate for a given individual. Results vary.

Where this information comes from

FDA approvals for GLP-1 products such as WEGOVY are specific to a particular product, route, dose, and indication and do NOT transfer to compounded semaglutide, unapproved GLP-1 formulations, or investigational peptide stacks (e.g. BPC-157, MOTS-c, TB-500). FDA has flagged dosing errors with compounded semaglutide and safety risks with several bulk peptide substances. Programs at EBO2 remain physician-supervised.

• WEGOVY (semaglutide) — FDA prescribing label

  DailyMed (U.S. National Library of Medicine)

  Current FDA-approved prescribing information for WEGOVY, defining approved indication, dosing, route, and safety information. Approval is product/route/indication-specific.

• FDA alerts providers, compounders, and patients to dosing errors with compounded semaglutide

  U.S. Food & Drug Administration

  FDA safety alert on dosing errors associated with compounded semaglutide. Regulatory/safety context only; does not endorse compounded products.

• FDA intends to take action against non-FDA-approved GLP-1 drugs

  U.S. Food & Drug Administration

  FDA statement on planned enforcement against non-FDA-approved GLP-1 products. Regulatory context; not a recommendation for any specific program.

• FDA — Certain Bulk Drug Substances Used to Compound Drug Products May Present Significant Safety Risks

  U.S. Food & Drug Administration

  FDA safety-risk framing for bulk drug substances used in compounding — the category that covers BPC-157, MOTS-c, TB-500, and related investigational peptides. Risk/regulatory context only.

• FDA — Unapproved Drugs enforcement policy overview

  U.S. Food & Drug Administration

  FDA overview of how the agency treats drugs that lack FDA approval, providing regulatory context for compounded and unapproved products.

References describe general evidence, safety, or regulatory context. They do not establish an individual benefit for any specific person, and they do not validate EBO2's proprietary clinic protocols.